Teriflunomide slows BVL in relapsing MS
A reanalysis of the TEMSO MRI data set using SIENA

ABSTRACT

Objective: To assess, using structural image evaluation using normalization of atrophy (SIENA), the effect of teriflunomide, a once-daily oral immunomodulator, on brain volume loss (BVL) in patients with relapsing forms of MS enrolled in the phase 3 TEMSO study.

Methods: TEMSO MR scans were analyzed (study personnel masked to treatment allocation) using SIENA to assess brain volume changes between baseline and years 1 and 2 in patients treated with placebo or teriflunomide. Treatment group comparisons were made via rank analysis of covariance.

Results: Data from 969 patient MRI visits were included in this analysis: 808 patients had baseline and year 1 MRI; 709 patients had baseline and year 2 MRI. Median percentage BVL from baseline to year 1 and year 2 for placebo was 0.61% and 1.29%, respectively, and for teriflunomide 14 mg, 0.39% and 0.90%, respectively. BVL was lower for teriflunomide 14 mg vs placebo at year 1 (36.9% relative reduction, \( p = 0.0001 \)) and year 2 (30.6% relative reduction, \( p = 0.0001 \)). Teriflunomide 7 mg was also associated with significant reduction in BVL vs placebo over the 2-year study. The significant effects of teriflunomide 14 mg on BVL were observed in both patients with and without on-study disability worsening.

Conclusions: The significant reduction of BVL vs placebo over 2 years achieved with teriflunomide is consistent with its effects on delaying disability worsening and suggests a neuroprotective potential.

Classification of evidence: Class II evidence shows that teriflunomide treatment significantly reduces BVL over 2 years vs placebo.

ClinicalTrials.gov identifier: NCT00134563. *Neural Neuroimmunol Neuroinflamm 2017;4:e390; doi: 10.1212/NXI.0000000000000390*

GLOSSARY

BPF = brain parenchymal fraction; BVL = brain volume loss; CDW = confirmed disability worsening; DMT = disease-modifying therapy; EAE = experimental autoimmune encephalitis; EDSS = Expanded Disability Status Scale; MRIAP = MRI analysis package; SIENA = structural image evaluation using normalization of atrophy; SIENAX = SIENA cross-sectional method.

Accelerated brain volume loss (BVL) starts in the early stages of MS and is associated with accumulating physical and cognitive disability.\(^1-5\) In a recent meta-analysis of clinical trials including patients with relapsing-remitting MS, treatment effects of disease-modifying therapies (DMTs) on BVL showed a strong correlation with treatment effects on disability worsening over 2 years.\(^6\)

In 2 phase 3 pivotal trials (TEMSO, NCT00134563, and TOWER, NCT00751881), teriflunomide 14 mg (AUBAGIO, Genzyme, Cambridge, MA), a once-daily oral immunomodulator approved for relapsing-remitting MS,\(^7-9\) significantly reduced the risk of 12-week
confirmed disability worsening (CDW) in patients with relapsing MS. A significant reduction in annualized relapse rate in both studies and a reduction in MRI activity in TEMSO were also reported (no MRI was performed in TOWER). BVL was assessed in TEMSO by changes in brain parenchymal fraction (BPF) using an MRI analysis package (MRIAP), developed and performed at UTHealth, Houston, TX. The results demonstrated numerical reduction of BVL by $\sim 25\%$ with teriflunomide 14 mg vs placebo, but this was not statistically significant. The MRIAP method has had limited use in successful large phase 3 studies in MS; therefore, it is difficult to assess its sensitivity for detecting change and therapeutic effects across different DMTs. Structural image evaluation using normalization of atrophy (SIENA) is a well-established, longitudinal, registration-based technique with a low error rate in detecting brain volume changes over time.

Given the consistent and statistically significant effects of teriflunomide on reducing the risk of disability worsening, and the strong association between BVL and disability worsening in MS, a new masked analysis of TEMSO MRI was undertaken using SIENA.

**METHODS**

**Standard protocol approvals, registrations, and patient consents.** The TEMSO study (ClinicalTrials.gov identifier NCT00134563) was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by central and local ethics committees and the respective institutional review board; patients provided written informed consent before entering the study.

**Study design.** TEMSO was a 2-year, phase 3, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of teriflunomide in reducing the frequency of relapses and progression of physical disability in patients who had relapsing MS, as reported previously. After a screening phase of up to 4 weeks, eligible patients were randomly assigned (in a 1:1:1 ratio) to receive a once-daily oral dose of placebo, 7 mg of teriflunomide, or 14 mg of teriflunomide for 108 weeks.

The primary objective of the SIENA reanalysis of the TEMSO MRI data set was to evaluate the effect of teriflunomide vs placebo on BVL from baseline to year 1 and year 2.

**MRI analysis.** MR scans collected from the TEMSO study at baseline and at weeks 48 (year 1) and 108 (year 2) were analyzed using the SIENA method, as performed at the Medical Image Analysis Center (MIAC AG, Basel, Switzerland). Further details of the specific SIENA methodology used for this analysis are provided in the supplementary material. SIENA was applied to 3-mm thick precontrast T1-weighted images of a 70-mm central brain area section (Montreal Neurological Institute Z coordinates $-10$ to $+60$ mm), which was selected for optimal reproducibility and comparability to previous trials of other oral DMTs. 15–21 MR images of 2 time points were coregistered, and surface changes were determined using the fully automated algorithm to estimate brain volume changes (figure e-1 at Neurology.org/nm).

In addition, the single-point SIENA cross-sectional method (SIENAX) was also applied to the T1-weighted images to estimate the normalized whole-brain volume of each patient at baseline (figure e-2).

Study personnel were masked to treatment allocation and other study data. A rigorous quality control of all uploaded MRI data and all stages of the SIENA analysis was performed. This led to the exclusion of some scans for 1 or more of the following reasons: required MRI sequence(s) for the evaluation were missing, quality of MRI sequence(s) was insufficient for the evaluation, and reference or longitudinal follow-up MRI was missing or excluded from the analysis for one of the aforementioned reasons.

**Statistical analysis.** The change from baseline in annualized percentage brain volume was analyzed, and median (95% CI) values were determined for each treatment group. Treatment group comparisons were made via nonparametric analysis of covariance, adjusted for region, age, Expanded Disability Status Scale (EDSS) strata, and normalized brain volume (using SIENAX). A similar method was applied for treatment group comparisons in a subgroup analysis of BVL in patients with or without on-study CDW, defined as an increase from baseline of at least 1.0 point in the EDSS score (or at least 0.5 points for patients with a baseline EDSS score greater than 5.5) that persisted for at least 12 or 24 weeks. The relationship between CDW and BVL was evaluated using a Cox model with CDW as the dependent variable and BVL as the independent variable, together with other covariates (treatment and stratification factors used for randomization). As this SIENA analysis was a masked reanalysis, but not a prospectively defined analysis as per the TEMSO protocol, no formal adjustment for multiplicity was performed.

**Classification of evidence.** This study provides Class II evidence of reduction in BVL, as assessed by masked SIENA analysis, over 2 years of treatment with once-daily oral teriflunomide 7 mg or 14 mg, compared with placebo, in patients with relapsing forms of MS.

**RESULTS**

Patients. At each time point, $\geq 89.5\%$ of the patient scans included in the original MRI analysis of the TEMSO study (described as the TEMSO MRI population below) were deemed suitable for inclusion at the corresponding time point in the SIENA analysis: 969 patients had baseline MRI; 808 had baseline and year 1 MRI (scans from 95/903 patients [10.5%] with evaluable MRI in the TEMSO MRI population, were excluded at year 1, before SIENA analysis); and 709 had baseline and year 2 MRI (scans from 69/778 patients [8.9%] were excluded at year 2). The mean (SD) normalized brain volume values at baseline for those patients included in the SIENA analysis were similar between the 3 treatment groups: 1,508.9 cm$^3$ (77.9 cm$^3$), 1,507.8 cm$^3$ (83.1 cm$^3$), and 1,502.7 cm$^3$ (75.8 cm$^3$), for placebo and teriflunomide 7 and 14 mg, respectively ($p = 0.5610$; for the comparison between groups of baseline normalized brain volume).
Baseline demographics and clinical characteristics of patients included in the SIENA analysis were similar to those of patients in the previously published TEMSO MRI population (table), including between-treatment comparisons (data not shown). Furthermore, the annualized relapse rate was consistent between both populations with respect to the comparison between placebo-treated patients (TEMSO MRI population: 0.517; SIENA: 0.509) and between patients treated with teriflunomide 14 mg (TEMSO MRI population: 0.343; SIENA: 0.330). The percentage of patients with CDW was also comparable within the placebo-treated patients (TEMSO MRI population: 25.2%; SIENA: 23.6%) and the teriflunomide 14 mg–treated patients (TEMSO MRI population: 18.8%; SIENA: 19.8%) in both study populations. These data demonstrate that the exclusion of a small number of scans, due to stringent quality control as done for the SIENA analysis, did not bias the final outcomes.

**SIENA analysis.** At both time points analyzed, teriflunomide 7 and 14 mg significantly slowed BVL compared with placebo (figure 1A). The difference in BVL with teriflunomide at year 1 (vs placebo) was maintained at year 2. Analysis of BVL in patients with MRI for all 3 time points (i.e., baseline, year 1, and year 2) demonstrated a similar pattern (figure 1B).

In a sensitivity analysis, exclusion of patients who had been included in the original TEMSO MRI population (assessed using MRIAP) but who did not have MRI data of sufficient quality for the SIENA analysis did not affect the overall findings. This was demonstrated by similar patterns of brain volume changes (as assessed by changes in BPF using MRIAP) between the groups analyzed: those to be included in the new SIENA analysis only, those included in the original TEMSO MRI population only, and those excluded from the new SIENA analysis (figure e-3).

**Relationship between on-study disability worsening and BVL.** In a Cox model, BVL over 2 years had an effect on CDW: risk reduction of 11% for every 1% change in brain volume ($p = 0.0203$).

The normalized brain volume at baseline was lower in the patient subgroup with subsequent on-study disability worsening vs the subgroup without disability worsening. At baseline, patients with and without 12-week CDW had mean (SD) brain volumes of 1,495 cm$^3$ (83.4 cm$^3$) and 1,509 cm$^3$ (77.6 cm$^3$), respectively; $p = 0.02$. Patients with and without 24-week CDW had brain volumes of 1,493 cm$^3$ (86.7 cm$^3$) and 1,509 cm$^3$ (77.5 cm$^3$), respectively; $p = 0.03$.

Placebo-treated patients demonstrated increased rates of BVL if they also had on-study disability worsening vs those without worsening (figure 2A). Of note, BVL remained statistically significantly lower in patients treated with teriflunomide 14 mg than in placebo-treated patients, regardless of the presence or absence of on-study disability worsening at both years 1 and 2 (figure 2, B and C). The median percentage change from baseline in patients treated with teriflunomide 14 mg with vs without on-study 12-week CDW at year 1 was $-0.25$ vs $-0.40$ ($p = 0.48$), respectively, and at year 2 was $-0.90$ vs $-0.87$ ($p = 0.68$), respectively.

A similar pattern of reduced BVL was observed in patients receiving teriflunomide 7 mg, although results did not reach statistical significance in the subgroup of patients without 12- or 24-week CDW from baseline to year 2 (figure e-4, A and B).

**DISCUSSION** Limiting BVL in MS is increasingly recognized as an evolving and important therapeutic goal, despite challenges of measurement at an individual patient level. The importance of BVL is due, in part, to the recognized association between BVL and long-term accumulation of physical and cognitive disability, which reduce both patients’ functional ability and their quality of life. Accelerated BVL can be evident from the earliest stages of MS, which highlights the need for early and effective intervention. In this masked reanalysis of the TEMSO MRI data set using the SIENA method, teriflunomide significantly slowed BVL vs placebo, an effect that was maintained to the end of the TEMSO core study.

SIENA is a well-established longitudinal registration-based technique with a low error rate in detecting brain...
volume changes over time\textsuperscript{13,14} and has been repeatedly used to measure treatment effects on brain atrophy with oral DMTs other than teriflunomide.\textsuperscript{15–21} SIENA can outperform many cross-sectional methods regarding sensitivity and reproducibility\textsuperscript{13,24} and, thus, may be better suited for this purpose.\textsuperscript{12}

This analysis of TEMSO MRI using the SIENA methodology was conducted using the same procedures as in other phase 3 studies of oral DMTs,\textsuperscript{15–21} with study personnel masked to treatment allocation and other study data. By applying rigorous quality-control criteria, some TEMSO MRIs were excluded in this reanalysis. It is acknowledged that exclusion of scans as a result of rigorous quality-control has the potential to introduce selection bias. Nonetheless, a sensitivity analysis demonstrated that exclusion of some TEMSO MRI did not affect baseline or other characteristics of the patients assessed.

The significant reduction in BVL observed in this analysis is consistent with the positive effect of teriflunomide on disability worsening already initially observed in a phase 2 study and later confirmed in both phase 3 studies: TEMSO and TOWER, which compared teriflunomide with placebo in patients with

\textbf{Figure 1} Annualized percentage brain volume change


data from Figure 1:

- **A**
  - Baseline to year 1
  - Baseline to year 2
  - Placebo: n = 276, -0.61, 34.4\%* (p = 0.0011); n = 234, -1.29, 27.6\%* (p = 0.0019)
  - Teriflunomide 7 mg: n = 269, -0.4, 36.9\%* (p = 0.0001)
  - Teriflunomide 14 mg: n = 263, -0.39, 30.6\%* (p = 0.0001)

- **B**
  - Baseline to year 1
  - Baseline to year 2
  - Placebo: n = 229, -0.57, 29.8\%* (p = 0.0021); n = 224, -1.3, 31.9\%* (p = 0.0008)
  - Teriflunomide 7 mg: n = 229, -0.4, 40.5\%* (p < 0.0001)
  - Teriflunomide 14 mg: n = 224, -0.87, 33.3\%* (p = 0.0001)

Annualized median percentage change from baseline in BVL over 2 years for teriflunomide 14 and 7 mg vs placebo: (A) using all scans available at each time point; (B) for patients with complete scan series at all time points. BVL = brain volume loss; CI = confidence interval; *Relative change vs placebo.
relapsing forms of MS. Our additional analysis showing faster rates of BVL in placebo-treated patients with on-study disability worsening compared with those without worsening provides further evidence that greater BVL is related to an increased risk of disability worsening. On-study disability worsening may also reflect the clinical manifestations of accumulated BVL before the start of the TEMSO study, as evidenced by lower baseline brain volumes in the subgroup with disability worsening vs the
subgroup without. Nevertheless, treatment with teriflunomide was associated with a significant reduction in BVL, regardless of the presence of on-study disability worsening, suggesting that teriflunomide exerts this effect in a broad range of patients with MS.

In a meta-analysis of data from 13 randomized clinical trials evaluating DMTs in patients with RRMS, the size of the treatment effect on brain atrophy was closely correlated with the size of treatment effect on 2-year disability worsening at the trial level ($R^2 = 0.48$). The meta-analysis included the data from the original MRIAP analysis of BPF changes conducted in TEMSO. When the 13-trial meta-analysis was repeated, replacing the MRIAP analysis of TEMSO MRI with the SIENA analysis of BVL, the $R^2$ values for the treatment effect correlation between brain atrophy and disability worsening strengthened from 0.48 to 0.61.

Preservation of brain volume with teriflunomide is consistent with its proposed mechanism of action in MS. The primary mechanism of action of teriflunomide is believed to relate to the reversible inhibition of proliferation of activated T and B lymphocytes, thereby limiting their involvement in damaging processes within the CNS. Studies of teriflunomide administered to rats with experimental autoimmune encephalitis (EAE) at disease onset showed reduced lymphocyte counts in the rats’ spinal cords. EAE animals dosed therapeutically with teriflunomide showed reduced CNS inflammation, reduced disease scores, reduced axonal damage and demyelination, and preserved sensory and motor neuronal function compared with untreated EAE animals. However, whether these results are driven solely by the anti-inflammatory effects of the drug acting in the periphery is currently unclear. Evidence is emerging that teriflunomide is found in the CNS at pharmacologically relevant concentrations and that teriflunomide treatment in vitro has direct effects on activated rodent microglia and astrocyte functions, suggesting that teriflunomide may have potential neuroprotective effects within the CNS, at least in rodents.

In this new analysis, teriflunomide—an immunomodulatory DMT with established efficacy on annualized relapse rate, disability worsening, and MRI lesion activity—has been demonstrated to reduce BVL. This result—besides indicating a neuroprotective potential of teriflunomide—further strengthens the evidence of a link between BVL and disability worsening.

**ACKNOWLEDGMENT**
The authors acknowledge the contribution of the TEMSO study investigators, the members of UTHHealth, Houston, TX, the central MRI center for the TEMSO Study, and Pascal Kuster and Stefan Traud of MIAC AG for their technical assistance and support in data preparation and processing pipeline handling. This manuscript was reviewed by Larisa Miller, PharmD, of Sanofi Genzyme. Drafting and editorial support for this manuscript were provided by Jessica Donaldson and Fiona Woodward, of Fishawack Communications Ltd. (Abingdon, UK), and was funded by Sanofi Genzyme.

**STUDY FUNDING**
Supported by Sanofi Genzyme.

**DISCLOSURE**
E.-W. Radue received speaker honoraria and travel compensation from Bayer Schering, Biogen, Fondazione Italiana Sclerosi Multipla, Genzyme, Novartis, Merck Serono, MorphoSys, and Synthon; consulted for Bayer Schering, Biogen Idec, Fondazione Italiana Sclerosi Multipla, Genzyme, Novartis, Merck Serono, Synthon, and MorphoSys; and received institutional research support from Novartis, Biogen Idec, Actelion, Basilea, SAKK, and Synarc. T. Sprenger served on the scientific advisory board for Sanofi Genzyme, Novartis, Actelion, Electrocore, and Mitsubishi Pharma; received speaker honoraria from Biogen, Sanofi Genzyme, Teva, Novartis, and Desitin; and received research support from Novartis Pharma, EFIC-Grunental, Swiss National Science Foundation, and Swiss MS Society. L. Gaetano served on the scientific advisory board for Novartis Pharma AG and interned for Novartis Pharma AG. N. Mueller-Lenke reports no disclosures. S. Cavalier is employed by Sanofi Genzyme. K. Thangavelu is employed by Sanofi Genzyme. M.A. Panzara was previously employed by Sanofi Genzyme and is currently employed by WAVE Life Sciences. J. E. Donaldson is employed by Fishawack Communications Ltd. F. M. Woodward is employed by Fishawack Communications Ltd. J. Wuestefel served on the scientific advisory board for Novartis, Biogen, Genzyme, Teva, and Roche; received travel support and/or speaker honoraria from Bayer, Biogen, and Novartis; is employed by MI-AC AG; and received research support from the German Ministry of Education and Research and the German Ministry of Economy. J. S. Wolinsky served on the scientific advisory board for AbbVie, Alkermes, Bayer Healthcare, Biogen, Biostem, Celgene, Clene Nanomedicine, EMD Serono, Forward PharmA A/S, MedDay, Novartis, Roche/Genentech, Sanofi/Genzyme, Takeda, and Teva; received travel funding and/or speaker honoraria from Academic CME, ACTRIMS, CMSC, ECTRIMS, Masters MS, Medscape, PRIME, and WebMD; served on the editorial board for Multiple Sclerosis Journal and Multiple Sclerosis and Related Diseases; holds a patent for Methods for treating CNS Lesions; consulted for AbbVie, Alkermes, Bayer Healthcare, Biogen, Biostem, Celgene, Clene Nanomedicine, Forward PharmA A/S, EMD Serono, Novartis, Roche/Genentech, Sanofi/Genzyme, Misupel, and Teva; received research support from NIH; and received royalties for monoclonal antibodies out-licensed through the University of Texas Health Science Center at Houston to Millipore. L. Kappos served on the editorial board for Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders, and Journal of Neurology; received research support from Actelion, Alkermes, Almirall, Bayer, Biogen, Excemed, GenoNeuro SA, Genzyme, Merck, Mitsubishi Pharma, Novartis, Receptos, Roche, Sanofi-Aventis, Santhera, Teva, Vianex, the Swiss MS Society, the Swiss National Research Foundation, the European Union, and Roche Research Foundations; and receives license fees for Neurostatus products paid directly to University Hospital Basel. Go to Neurology.org/nm for full disclosure forms.

**AUTHOR CONTRIBUTIONS**
E.-W. Radue, T. Sprenger, L. Gaetano, N. Mueller-Lenke, S. Cavalier, M.A. Panzara, J. Wuestefel, J.S. Wolinsky, and L. Kappos: design or conceptualization of the study and/or analysis or interpretation of the data. L. Gaetano and K. Thangavelu: analysis or interpretation of the data. E.-W. Radue, T. Sprenger, L. Gaetano, N. Mueller-Lenke, S. Cavalier, K. Thangavelu, M.A. Panzara, J.E. Donaldson, F.M. Woodward, J. Wuestefel, J.S. Wolinsky, and L. Kappos: drafting or revising the manuscript for intellectual content.

**DISCLOSURE**
E.-W. Radue received speaker honoraria and travel compensation from Bayer Schering, Biogen, Fondazione Italiana Sclerosi Multipla, Genzyme, Novartis, Merck Serono, MorphoSys, and Synthon; consulted for Bayer Schering, Biogen Idec, Fondazione Italiana Sclerosi Multipla, Genzyme, Novartis, Merck Serono, Synthon, and MorphoSys; and received institutional research support from Novartis, Biogen Idec, Actelion, Basilea, SAKK, and Synarc. T. Sprenger served on the scientific advisory board for Sanofi Genzyme, Novartis, Actelion, Electrocore, and Mitsubishi Pharma; received speaker honoraria from Biogen, Sanofi Genzyme, Teva, Novartis, and Desitin; and received research support from Novartis Pharma, EFIC-Grunental, Swiss National Science Foundation, and Swiss MS Society. L. Gaetano served on the scientific advisory board for Novartis Pharma AG and interned for Novartis Pharma AG. N. Mueller-Lenke reports no disclosures. S. Cavalier is employed by Sanofi Genzyme. K. Thangavelu is employed by Sanofi Genzyme. M.A. Panzara was previously employed by Sanofi Genzyme and is currently employed by WAVE Life Sciences. J. E. Donaldson is employed by Fishawack Communications Ltd. F. M. Woodward is employed by Fishawack Communications Ltd. J. Wuestefel served on the scientific advisory board for Novartis, Biogen, Genzyme, Teva, and Roche; received travel support and/or speaker honoraria from Bayer, Biogen, and Novartis; is employed by MI-AC AG; and received research support from the German Ministry of Education and Research and the German Ministry of Economy. J. S. Wolinsky served on the scientific advisory board for AbbVie, Alkermes, Bayer Healthcare, Biogen, Biostem, Celgene, Clene Nanomedicine, EMD Serono, Forward PharmA A/S, MedDay, Novartis, Roche/Genentech, Sanofi/Genzyme, Takeda, and Teva; received travel funding and/or speaker honoraria from Academic CME, ACTRIMS, CMSC, ECTRIMS, Masters MS, Medscape, PRIME, and WebMD; served on the editorial board for Multiple Sclerosis Journal and Multiple Sclerosis and Related Diseases; holds a patent for Methods for treating CNS Lesions; consulted for AbbVie, Alkermes, Bayer Healthcare, Biogen, Biostem, Celgene, Clene Nanomedicine, Forward PharmA A/S, EMD Serono, Novartis, Roche/Genentech, Sanofi/Genzyme, Misupel, and Teva; received research support from NIH; and received royalties for monoclonal antibodies out-licensed through the University of Texas Health Science Center at Houston to Millipore. L. Kappos served on the editorial board for Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders, and Journal of Neurology; received research support from Actelion, Alkermes, Almirall, Bayer, Biogen, Excemed, GenoNeuro SA, Genzyme, Merck, Mitsubishi Pharma, Novartis, Receptos, Roche, Sanofi-Aventis, Santhera, Teva, Vianex, the Swiss MS Society, the Swiss National Research Foundation, the European Union, and Roche Research Foundations; and receives license fees for Neurostatus products paid directly to University Hospital Basel. Go to Neurology.org/nm for full disclosure forms.

**AUTHOR CONTRIBUTIONS**
E.-W. Radue, T. Sprenger, L. Gaetano, N. Mueller-Lenke, S. Cavalier, M.A. Panzara, J. Wuestefel, J.S. Wolinsky, and L. Kappos: design or conceptualization of the study and/or analysis or interpretation of the data. L. Gaetano and K. Thangavelu: analysis or interpretation of the data. E.-W. Radue, T. Sprenger, L. Gaetano, N. Mueller-Lenke, S. Cavalier, K. Thangavelu, M.A. Panzara, J.E. Donaldson, F.M. Woodward, J. Wuestefel, J.S. Wolinsky, and L. Kappos: drafting or revising the manuscript for intellectual content.
REFERENCES

1. De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014;28:147–156.

2. Riley C, Azevedo C, Bailey M, Pelletier D. Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques. Expert Rev Neurother 2012;12:323–333.

3. Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;84:1082–1091.

4. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:1144–1150.

5. Marcus JF, Waubant EL. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist 2013;3:65–80.

6. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014;75:43–49.

7. Genzyme. AUBAGIO (Summary of Product Characteristics). Available at: ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf. Accessed December 5, 2016.

8. Genzyme. AUBAGIO (Package Insert). Available at: accessdata.fda.gov/drugsatfda_docs/label/2016/202992s002lbl.pdf. Accessed December 8, 2016.

9. Bar-Or A, Pachter A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74:659–674.

10. O’Connor P, Wolinsky JS, Conflavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293–1303.

11. Conflavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247–256.

12. Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013;19:1310–1319.

13. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–489.

14. Smith SM, Zhang Y, Jenkinson M, et al. TR01SMS1: Brain Atrophy Analysis Using Single- and Multiple-Time-Point Data. FMRIIB Technical Note. 2001. Available at: fmrilib.ox.ac.uk/datasets/techrep/tr01s1/tr01s1.pdf. Accessed February 3, 2017.

15. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401.

16. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545–556.

17. Radue EW, Goodin D, Jeffery D, et al. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing–remitting multiple sclerosis: results from the phase 3 FREEDOMS II study. Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10–13, 2012; Lyon, France.

18. Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol 2014;261:1794–1802.

19. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098–1107.

20. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087–1097.

21. Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology 2015;84:1145–1152.

22. Radue EW, Barkhof F, Kappos L, et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology 2015;84:784–793.

23. Mowry EM, Beheشتian A, Waubant E, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72:1760–1765.

24. Durand-Dubief F, Belaroussi B, Armspach JP, et al. Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. AJNR Am J Neuroradiol 2013;34:1918–1924.

25. Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X. Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J Neurol 2015;262:2617–2626.

26. Sormani MP, Radue EW, Sprenger T, et al. Incorporating the TEMSO SIENA analysis improves correlation of brain atrophy and disability progression. Presented at the 2nd Congress of the European Academy of Neurology: May 28–31, 2016; Copenhagen, Denmark.

27. Li L, Liu J, Dolohery T, Zhang D, Arendt C, Jones C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol 2013;265:82–90.

28. Ringheim GE, Lee L, Laws-Ricker L, et al. Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis. Front Neurol 2013;4:169.

29. Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol Neurosurg Psychiatry 2009;72:1147–1150.

30. Edling E, Woodworth L, Agrawal R, et al. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation–induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2013;347:203–211.

31. Edling E, Woodworth L, Agrawal R, et al. Teriflunomide impacts primary microglia and astrocyte functions in vitro. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 14–17, 2016; London, UK.